Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGEC2 is a cancer/testis antigen expressed in various tumors but minimally in normal tissues (except testis). Its expression is linked to oncogenic activation and poor prognosis, making it an attractive target for cancer immunotherapy, particularly TCR-based therapies. It is involved in tumorigenesis by interfering with tumor suppressor pathways.
TCR gene therapy targeting specific epitopes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAGE family member C2 (MAGEC2).